One of my favorite components of my career has been building a leading clinical trial program at our practice. Clinical science has allowed me to offer cutting-edge treatments in my community while ...

An Indonesian study of the characteristics of the retinal vasculature found that the retinal vessel tortuosity (VT) was significantly higher and the fractal dimension (FD) was significantly lower in ...

Anat Loewenstein, MD, spoke with Modern Retina about her presentation of AXPAXLI trial results and upcoming trials for this potential treatment, which she gave at Clinical Trials at the Summit meeting ...

June 2nd 2025. Two FDA-approved geographic atrophy treatments show significant patient dropout, with 45% discontinuation by 18 months, driven by baseline vision, CNV, and lack of immediate visual ...

In RESTORE (NCT04945772), a randomized, multicenter, sham-controlled phase 2 clinical trial of 27 patients with severe vision loss from advanced RP, no better than logMAR +1.9 (20/1600 Snellen ...

In a recent study, the researchers suggested that targeting the circuits responsible for visual acuity may be necessary in achieving optimal recovery of visual function and could aid in the ...

The US Food and Drug Administration (FDA) has granted clearance for OcuSciences, Inc.’s flagship device OcuMet Beacon, the company announced in a press release. 1 The company said it will soon be ...

Chengdu Origen Biotechnology Co, Ltd. And Vanotech Ltd. recently announced the dosing of the first patient in the VAN-2401 multi-center phase 1 clinical trial (NCT06825858). 1 The VAN-2401 clinical ...

The National Eye Institute awarded a $423,500 grant to support research focused on the diagnosis and treatment of uveitis. Siamak Yousefi, PhD, associate professor at the University of Tennessee Health ...

The European Commission (EC) granted marketing authorization for Afqlir (aflibercept), which is a 2 mg vial kit and pre-filled syringe for intravitreal injection. This is a biosimilar to reference ...

Rahul Khurana, MD, discusses his 2022 ASRS talk, “Phase 2 Study of THR-149, a Plasma Kallikrein Inhibitor in Patients With DME Who Respond Suboptimally to Anti-VEGF Treatment (Month 6 Results of Part ...

Biotechnology company Lineage Cell Therapeutics recently announced it will be presenting data from its phase 1/2a clinical study (NCT02286089) at the upcoming Clinical Trials at the Summit (CTS) 2025 ...